$Nektar Therapeutics (NKTR.US)$
Can Nektar's T-cell Therapy Revolutionize Alopecia Treatment? Phase 2b Trial Fully Enrolled

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
Wednesday, 26th February at 7:00 am
SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.
Re...

$Nektar Therapeutics (NKTR.US)$
This Phase 2 trial announcement represents a strategic advancement in Nektar's development of rezpegaldesleukin for type 1 diabetes treatment. The collaboration with TrialNet, a leading international diabetes research network, significantly enhances the trial's credibility and execution potential. The study's design is particularly robust, incorporating both mixed meal tolerance testing and C-peptide preservation measurements - important ma...

$Nektar Therapeutics (NKTR.US)$
Can This New Diabetes Treatment Change T1D Patient Care? Major Trial Announced

$Nektar Therapeutics (NKTR.US)$ 🚀🚀

smallest win! hahahahah. so stupid but fun.
$Nektar Therapeutics (NKTR.US)$

$Nektar Therapeutics (NKTR.US)$
taking a position here

$Nektar Therapeutics (NKTR.US)$
The FDA's Fast Track designation for rezpegaldesleukin marks a important inflection point for Nektar Therapeutics in the $14 billion global atopic dermatitis market. The designation's significance extends beyond mere regulatory acceleration - it validates the drug's novel approach in a highly competitive landscape dominated by JAK inhibitors and biologics like Dupixent.
The drug's mechanism of action targeting regulatory T c...

$Nektar Therapeutics (NKTR.US)$
Nektar's Breakthrough: FDA Accelerates Path for Revolutionary Skin Disease Treatment

$Nektar Therapeutics (NKTR.US)$ Reuters· 1 min ago
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis